Table 1

Correlation between I scintigraphy and NIS expression

T3aT4TSH μIU/mlScintiscanThyroid uptake 123I @ 24 hbThyroid uptake 131I @ 24 hbMetastasisTissuesNIS expressionEstrogen receptor in index tumor or metastasisOngoing therapy
% Uptake of ingested dose(Index tumor or metastasis)
199mTcO4M (soft tissue)Neg+
2 c 99m TcO 4 M (soft tissue) Pos +
399mTcO4INeg++
4 99m TcO 4 1% M (soft tissue) Pos
599mTcO4INeg++
699mTcO4INeg+
799mTcO4INeg+
8123IINeg++
9123IM (soft tissue)Neg++
10 Xd 0.3 123 I 0% I Pos ++
11123I20.3%INeg++
12123I48%NANA++
13X4.2123I11%NANA++
14 X0.088123I1.4%2.5% (4 h)e 2.9% IPos+
X+ 0.031 131 I 0.22% (24 h) M (lung) Pos
MMI 0.048% (48 h)
0.035% (72 h)
15X0.036123I0.9%M (bone)Neg+
16X2.1123IMinimalM (lymph node)Neg
17 X 0.572 123 I 3.8% I Pos +
18X0.019123I2.0%NANA++
19X0.014123I1.4%NANA++
20X0.007f123I4.6%INeg++
21XNot done123I2.0%INeg+
M (soft tissue)Neg
22 X 0.018 123 I 1.7% I Pos +
23 X 0.135 123 I Trace I Pos
24 X 0.33 123 I 2.7% I (axillary lymph) Pos +
25X0.054123I2.8%M (soft tissue)Neg+
26X0.00123I1.99%I (recurrent breast)Neg+
27X0.079123I1.26%I (→metastasis)Neg++
Contralateral primaryPos+
  • Note: Bold designates the NIS-positive cases.

  • a T3, triiodothyronine; T4, thyroxine; TSH, thyroid-stimulating hormone; NIS, Na+/I symporter; M, metastasis; Neg, negative; Pos, positive; I, index or primary breast cancer; NA, not available; MMI, methimazole.

  • b Handheld probe.

  • c Bold designates the NIS-positive cases.

  • d Primary hypothyroidism.

  • e Scintigraphic calculation.

  • f Performed 1 week before scan.